Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: Role of nuclear factor-κB

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 995-1004

  La Frazla, Simone ^a   Amici, Carlo ^a   Santoro, M Gabriella ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARBOBENZOXYLEUCYLLEUCYLNORVALINAL; EPOXOMICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFECTED CELL PROTEIN 0; MG 115; PROTEASOME INHIBITOR; PROTEIN C JUN; PROTEIN FOS; STRESS ACTIVATED PROTEIN KINASE; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEP 2 CELL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DOWN-REGULATION; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; LEUPEPTINS; NF-KAPPA B; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION FACTOR AP-1; VERO CELLS;

EID: 33845604018     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Santoro MG, Rossi A, Amici C. NF-kappaB and virus infection: who controls whom. EMBO J 2003; 11:2552-2560.
2. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
3. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18:621-663.
4. Chu W, Ostertag D, Li ZW, et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity 1999; 11:721-731.
5. Di Donato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388:548-554.
6. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998; 395:297-300.
7. Rodriguez MS, Wright J, Thompson J, et al. Identification of lysine residues required for signal-induced ubiquitination and degradation of IkappaB-alpha in vivo. Oncogene 1996; 12:2425-2435.
8. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-310.
9. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 8:6853-6866.
10. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-227.
11. Rosemberg ZF, Fauci AS. Immunopathogenesis of HIV infection. MSEB J 1991; 5:2382-2390.
12. Nabel GJ, Rice SA, Knipe DM, Baltimore D. Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. Science 1988; 239:1239-1302.
13. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711-713.
14. Siddiqui A, Gaynor R, Srinivasan A, Mapoles J, Farr R. Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 1989; 169:479-484.
15. Sassone-Corsi P, Wildeman A, Chambon P. A trans-acting factor is responsible for the simian virus 40 enhancer activity in vitro. Nature 1985; 313:458-463.
16. De Meritt IB, Milford LE, Yurochko AD. Activation of the NF-κB pathway in human cytomegalovirus-infected cell is necessary for efficient transactivation of the major immediate-early promoter. J Virol 2004; 78:4498-4507.
17. Rong BL, Libermann TA, Kogawa K, et al. HSV-1-inducible proteins binds to NF-kappaB-like sites in the HSV-1 genome. Virology 1992; 189:750-756.
18. Roizman B, Knipe DM. Herpes simplex and their replication. In Field's Virology, 4th ed 2001; pp. 2399-2459. Edited by DM Knipe, P Howley. Philadelphia: USA: Lippincott, Williams & Wilkin.
19. Amici C, Belardo G, Rossi A, Santoro MG. Activation of IκB kinase by herpes simplex virus type 1. J Biol Chem 2001; 276:28759-28766.
20. Amici C, Rossi A, Costanzo A, et al. Herpes simplex virus disrupts NF-κB regulation by blocking its recruitment on the Biol promoter and directs the factor on viral genes. J Biol Chem 2006; 281:7110-7117.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65:55-63.
22. Rosenthal N. Identification of regulatory elements of cloned genes with functional assays. Methods Enzymol 1987; 152:704-720.
23. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000; 403:103-108.
24. Bernasconi D, Amici C, La Frazia S, Ianaro A, Santoro MG. The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J Biol Chem 2005; 25:24127-24134.
25. Zachos G, Clements B, Conner J. Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1 Biol Chem 1999; 274:5097-5103.
26. McLean TI, Bachenheimer SL. Activation of c-Jun N-terminal kinase by herpes simplex virus type 1 enhances viral replication. J Virol 1999; 73:8415-8426.
27. Mulhouse S, Kenny JJ, Quinn PG, Lee V, Wigdahl B. ATF/CREB elements in the herpes simplex virus type 1 latency-associated transcript promoter interact with members of the ATF/CREB and AP-1 transcription factor families. J Biomed Sci 1998; 5:451-464.
28. Gu W, Huang Q, Hayward GS. Multiple tandemly repeated binding sites for the YY1 represser and transcription factors AP-1 and SP-1 are clustered within intron-1 of the gene encoding the IE110 transactivator of herpes simplex virus type 1. J Biomed Sci 1995; 3:203-226.
29. Everett RD. ICP0, a regulator of herpes simplex virus during lytic and latent infection. BioEssay 2000; 22:761-770.
30. Donald MC, Shaffer PA. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nature Rev Drug Discov 2003; 2:278-288.
31. Patel A, Hanson J, McLean TI, et al. Herpes simplex type 1 induction of persistent nuclear translocation increases the efficiency of virus replication. Virology 1998; 247:212-222.
32. Gregory D, Hagett D, Holmes D, Money E, Bachenheimer SL. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway. J Virol 2004; 78:13582-13590.
33. Margolis DM, Rabson AB, Straus S, Ostrove JM. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186:788-791.
34. Amici C, Belardo G, Rozera C, Bernasconi D, Santoro MG. Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: role of IkappaB kinase (IKK). AIDS 2004 18:1271-1280.
35. Mikloska Z, Danis VA, Adams S, Lloyd AR, Adrian DL, Cunningham AL. In vivo production of cytokines and beta (C-C) chemokines in human recurrent herpes simplex lesions - do herpes simplex virus-infected keratinocytes contribute to their production? J Infect Dis 1998; 177:827-838.
36. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701.
37. Santoro MG. Antiviral activity of cyclopentenone prostanoids. Trends Microbiol 1997; 5:276-281.
38. 2 is a potent inhibitor of influenza A virus replication. Antimicrob Agents Chemother 2000; 44:200-204.
39. Tanaka A, Matsuoka H, Nishino H, Imanishi J. Antiherpetic action of prostaglandin D2. Prostaglandins Leukot Med 1986; 25:131-138.
40. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8:397-403.
41. Everett RD, Orr A, Preston CM. A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO J 1998; 17:7161-7169.
42. Burkham J, Coen DM, Hwang CB, Weller SK. Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments. J Virol 2001; 75:2353-2367.
43. Prosch S, Priemer C, Hoflich C, et al. Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. Antivir Ther 2003; 8:555-567.
44. Hobbs WE, DeLuca NA. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICPO. J Virol 1999; 73:8245-8255.
45. Hagglund R, Van Sant C, Lopez P, Roizman B. Herpes simplex virus 1-infected cell protein O contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA 2002; 99:631-636.
46. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibitors as therapeutics. Essays Biochem 2005; 41:205-218.